Symptom Management in Multiple Myeloma | Dana-Farber Cancer Institute

Bispecific Antibody Therapy in Multiple MyelomaПодробнее

Survivorship Series: Multiple Myeloma Survivorship Care- What Our Providers Think You Should KnowПодробнее

Updates on AL Amyloidosis Treatment: What is New in 2023 | Dana-Farber Cancer InstituteПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

HealthTree Podcast for Myeloma: Irene Ghobrial, MD, Dana Farber Cancer InstituteПодробнее

Young Patients with Multiple Myeloma and Complications | Shonali Midha, MD | ESMO22 PennsylvaniaПодробнее

Update in Multiple MyelomaПодробнее

Myeloma 101: Diagnosis, Prognosis & Risk | Dana-Farber Cancer InstituteПодробнее

Updates in Managing Bone Disease in Multiple Myeloma | Dana-Farber Cancer InstituteПодробнее

Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk: Nikhil C. Munshi, MDПодробнее

Diagnosis and Risk Assessment In Multiple MyelomaПодробнее

Symptom Management in Multiple Myeloma: Shonali Midha, MDПодробнее

Updates on Managing Bone Disease in Multiple Myeloma: Monique Hartley-Brown, MD, MMScПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Early Detection and Interception in Multiple Myeloma: Irene Ghobrial, MDПодробнее

Treating Myeloma at the Dana-Farber Cancer Institute | MCRT May 8, 2021Подробнее

Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MDПодробнее

Updates on AL Amyloidosis Treatment: What is New in 2022: Giada Bianchi, MDПодробнее

Dr. Paul G. Richardson Provides Study Updates on the Phase 3 DETERMINATION Trial for NDMM patientsПодробнее